Pfizer Inc PFE

$28.72 +0.05 (0.17%)

Valuation

Market cap
163,409,648,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.31
Forward PE
9.54
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
24,950,400
Avg volume
35,986,023
Day's range
$28.39 – $28.87
Shares out
5,699,674,000
Stochastic %K
90%
Beta
0.34
Analysts
Sell
Price target
$28.92

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

ProTraderColin Sep 28, 11:50 PM
$PFE will we finally see 30+ again?!!
0 replies
LoneBroker Sep 28, 9:49 PM 0 replies
Noobnr1 Sep 28, 9:01 PM
$NYXH go Liam Kelly make Nyxoah great(er) and let the stockprise follow please 🚀🚀🚀 $PHAR $GILD $PFE $OMER
1 replies
SellasgpsCurativeBAT11 Sep 28, 4:38 PM
$SLS $JNJ $BMY $PFE $AZN 4 Contenders. Let’s see who walks away with # 1 Oncology prize in a Millennia. GPS CURATIVE 20+ WT1 cancers. ✌️🙏❤️‍🩹
1 replies
STOCKPICKERTRADER Sep 28, 4:36 PM
$PFE keeps bringing positive updates - good to see! Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says MT NEWSWIRES Sep-28-2026 11:52 a.m. ET 11:52 AM EDT, 09/28/2026 (MT Newswires) -- Pfizer's (PFE) new phase 3 studies of tilrekimig in atopic dermatitis and asthma may drive upside if results are positive, UBS Securities said Friday in a report. The adult atopic-dermatitis study will be run head-to-head against Dupixent, which is developed jointly by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) , and UBS said the potential commercial contribution is not yet reflected in consensus estimates. Topline data released in March showed competitive placebo-adjusted EASI-75 rates of about 50% at the middle and high doses, and UBS said Pfizer (PFE) is likely working to maximize efficacy at the middle-dose level.
0 replies
LuckyEnzo Sep 28, 4:23 PM
@EquivalentExchange is on an absolute tear recently🔥the plays just keep getting better! If you’re not following yet you’re missing out. $GRML / $PFE get in cheap
0 replies
R0yalTEA Sep 28, 3:11 PM
Big Vax Week is Here! $PFE $MRNA They will Never Learn Don’t believe the Serpent and His Lies
1 replies
STOCKPICKERTRADER Sep 28, 2:27 PM
$PFE nice to see! https://finance.yahoo.com/healthcare/articles/pfizer-pfe-heads-esmo-45-140924840.html
0 replies